Timber pharmaceuticals receives european orphan designation for autosomal recessive congenital ichthyosis & positive comments on pediatric investigation plan for tmb-001 in autosomal recessive ci & x-linked recessive ichthyosis

- regulatory milestones improve path to filing a european marketing authorization application - - company plans to submit additional application for orphan designation in europe for tmb-001 for the treatment of x-linked recessive ichthyosis -
TMBR Ratings Summary
TMBR Quant Ranking